



Regulated information



Disclosure of acquisition of treasury shares

Waregem (Belgium) / Rotterdam (Netherlands)*, March 10, 2010 - Arseus discloses the information with respect to the acquisition of treasury shares required under the new Article 207 of the Royal Decree of January 30, 2001 implementing the Belgian Company Code.

Arseus today announces that during the period from March 2 to March 10, it acquired 52,883 treasury shares on Euronext Brussels.

Acquisition date	Number of shares	Average price	Lowest price	Highest price	Amount
2 March 2010	6,400	€ 8.6896	€ 8.46	€ 9.00	€ 55,613
3 March 2010	6,638	€ 8.8012	€ 8.60	€ 8.88	€ 58,422
4 March 2010	6,658	€ 8.8013	€ 8.67	€ 8.93	€ 58,599
5 March 2010	8,454	€ 9.0300	€ 8.84	€ 9.15	€ 76,340
8 March 2010	7,980	€ 9.0584	€ 8.95	€ 9.11	€ 72,286
9 March 2010	5,623	€ 9.1011	€ 9.07	€ 9.15	€ 51,175
10 March 2010	11,130	€ 9.1752	€ 9.12	€ 9.20	€ 102,120

The Extraordinary Shareholders' Meeting held on June 16, 2009 renewed the authorisation of the Board of Directors to acquire treasury shares.

For more information:

Constantijn van Rietschoten, Investor Relations Manager

+31 88 33 11 222 (Office)

+31 6 536 91 585 (Mobile)

constantijn.van.rietschoten@arseus.com

Arseus profile

Arseus is a multinational group of companies that supplies products, services and concepts to professionals and institutions in the European healthcare sector. Arseus is subdivided into four divisions and operates in the markets for pharmaceutical compounding for pharmacies, dental products, medical and surgical products, and medical IT-solutions. The Belgian company Arseus NV is located in Waregem, and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.

In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.

* This press release was sent out by Arseus NV and Arseus BV.